Aytu BioPharma, Inc. (LON:0A8M)

Market Cap	17.31M +101.5%
Revenue (ttm)	46.54M +2.0%
Net Income	-18.16M
EPS	-2.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,135
Average Volume	2,207
Open	2.200
Previous Close	1.680
Day's Range	2.200 - 2.200
52-Week Range	1.340 - 3.240
Beta	n/a
RSI	71.86
Earnings Date	Feb 3, 2026

About Aytu BioPharma

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatm...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Joshua Disbrow
• Employees: 83
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A8M

Financial Performance

In fiscal year 2025, Aytu BioPharma's revenue was $66.38 million, an increase of 1.84% compared to the previous year's $65.18 million. Losses were -$13.56 million, -14.40% less than in 2024.

Financial numbers in USD